-
Deferiprone: Iron Chelator for Cancer Biology & Metabolic Re
2026-04-21
Deferiprone, also known as 3-hydroxy-1,2-dimethylpyridin-4-one, is a selective iron chelator widely used in research to modulate iron-dependent cellular pathways. It enables precise investigation of apoptosis induction via iron depletion and protection against doxorubicin-induced cytotoxicity. Its stability and solubility profile make it a cornerstone for advanced studies in tumor iron metabolism.
-
HSP90 Inhibition Destabilizes METTL3 to Suppress MYC in CRC
2026-04-20
This study reveals a mechanistic link between HSP90 chaperone activity and the stabilization of METTL3, an m6A RNA methyltransferase, in colorectal cancer (CRC). By using 17-AAG to inhibit HSP90, the authors demonstrate enhanced proteasomal degradation of METTL3, leading to reduced MYC mRNA m6A modification and expression—highlighting a potential therapeutic target in CRC.
-
Vincristine Sulfate (A1765): Data-Driven Solutions for Cance
2026-04-20
This article addresses reproducibility and assay optimization challenges commonly faced by cancer researchers using vincristine sulfate. Drawing on validated data, it demonstrates how SKU A1765—Vincristine sulfate from APExBIO—delivers reliable performance for studies in acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL), and microtubule dynamics. Scenario-driven Q&As provide actionable guidance and evidence-based best practices.
-
Caspase Specificity Revealed: Insights from IL-18 Tetrapepti
2026-04-19
This study introduces a novel tetrapeptide-based inhibitor targeting caspase-8 and systematically maps the substrate and inhibitor specificity of both inflammatory and apoptotic caspases. Findings highlight unexpected cross-reactivity of established inhibitors such as VX-765, with implications for the interpretation of pyroptosis and inflammation research.
-
Dabigatran Etexilate: Advancing Oral Anticoagulation Beyond
2026-04-18
The reference paper presents a comprehensive clinical review of dabigatran etexilate, the first oral direct thrombin inhibitor approved for stroke prevention in nonvalvular atrial fibrillation and VTE prophylaxis. Its predictable pharmacokinetics, rapid onset of action, and lack of cytochrome P450 metabolism address major limitations of vitamin K antagonists and low molecular weight heparins, with significant implications for drug interaction research and clinical practice.
-
EZ Cap™ Cy5 EGFP mRNA (5-moUTP): Precision mRNA Delivery Wor
2026-04-17
EZ Cap™ Cy5 EGFP mRNA (5-moUTP) empowers researchers to simultaneously track mRNA uptake and protein expression, optimizing gene delivery and translation efficiency assays. With dual fluorescence, immune-evasive Cap1 structure, and robust workflow compatibility, this tool accelerates quantitative, reproducible, and immune-silent transfection studies.
-
CCG-1423: A RhoA Inhibitor Transforming Cancer & Viral Assay
2026-04-16
CCG-1423, a potent RhoA inhibitor from APExBIO, enables researchers to dissect RhoA/ROCK signaling with unmatched specificity in cancer and viral infection models. Learn how this tool advances workflows for apoptosis analysis, tight junction biology, and pathway-targeted intervention.
-
Berbamine Hydrochloride: NF-κB Activity Inhibitor in Cancer
2026-04-15
Berbamine hydrochloride is a potent NF-κB activity inhibitor with proven efficacy in cancer research. It demonstrates robust cytotoxicity in leukemia and hepatocellular carcinoma models and is widely utilized for dissecting tumorigenic signaling and ferroptosis resistance.
-
Salinomycin: Polyether Ionophore Antibiotic in HCC Research
2026-04-14
Salinomycin, a polyether ionophore antibiotic, is transforming hepatocellular carcinoma research by enabling precise targeting of cancer cell survival pathways. This article delivers data-driven workflows, advanced troubleshooting, and actionable insights to optimize assay reproducibility and mechanistic clarity in anti-cancer research.
-
Machine Learning-Driven Senolytic Discovery: Key Advances an
2026-04-13
This article examines the major innovation of Smer-Barreto et al., who applied machine learning to identify novel senolytics, validating several compounds that selectively eliminate senescent cells. The approach demonstrates cost-effective, data-driven drug discovery, with implications for aging, oncology, and translational senescence research.
-
Rapid AF Conversion: Vernakalant Hydrochloride Phase 3 Findi
2026-04-12
This article reviews the landmark phase 3 trial evaluating vernakalant hydrochloride for rapid pharmacological conversion of atrial fibrillation (AF) to sinus rhythm. The study's methodology, efficacy data, and safety profile are discussed, alongside implications for adrenergic signaling pathway research and translational cardiovascular models.
-
Calpeptin: Potent Calpain Inhibitor for Fibrosis Research
2026-04-12
Calpeptin is a nanomolar calpain inhibitor used in fibrosis and inflammation research. It reduces extracellular vesicle release and modulates pro-fibrotic signaling in vitro and in vivo. Supplied by APExBIO, Calpeptin offers high purity and validated efficacy in preclinical models.
-
Chloroquine in Cancer and Malaria Research: Protocols & Pitf
2026-04-11
Chloroquine, a gold-standard autophagy and Toll-like receptor inhibitor, offers proven utility in cancer, malaria, and autoimmune research. This guide delivers actionable workflow enhancements, troubleshooting strategies, and real-world assay insights to maximize reproducibility with APExBIO's high-purity Chloroquine (N4-(7-chloroquinolin-4-yl)-N1,N1-diethylpentane-1,4-diamine).
-
Nirmatrelvir (PF-07321332): Applied SARS-CoV-2 Research Guid
2026-04-11
Nirmatrelvir (PF-07321332) empowers antiviral researchers to dissect SARS-CoV-2 replication with precision by targeting the viral 3CL protease. This guide details optimized workflows, data-driven troubleshooting, and actionable insights for maximizing reproducibility and impact in COVID-19 therapeutic research.
-
Perphenazine: A Dopamine D2 Receptor Antagonist for Advan...
2026-04-10
Perphenazine stands out as a versatile dopamine antagonist for neuropharmacology research, delivering robust performance in cell death, immunomodulation, and host-pathogen interaction models. APExBIO’s high-quality Perphenazine empowers researchers to explore receptor signaling, mitochondrial apoptosis, and host-directed antibacterial strategies with confidence and reproducibility.